PDUFA VII Commitment Letter Outlines Real-Time Review Expansion, Hiring Goals
Executive Summary
Allergenic extract products, previously excluded, also will become part of the user fee program beginning in FY 2023.
You may also be interested in...
Industry Willing To Let US FDA Go Slowly With Real-Time Review Expansion
Program growth beyond supplements will be determined after the agency gains experience with STAR program, PhRMA executive tells the Pink Sheet.
US FDA’s Stein ‘Excited’ About Real-World Evidence, Rare Disease Endpoint Pilot Programs
Head of Office of New Drugs highlights programs being established under PDUFA VII that could help overcome obstacles in drug development.
PDUFA VII’s Big Commitments: ‘Goal Inflation’ Accelerates
Latest iteration of the Prescription Drug User Fee Act agreement negotiated by US FDA and the pharmaceutical industry continues the trend to ever larger sets of goals and commitments as part of the reauthorization process.